Searchable abstracts of presentations at key conferences in endocrinology

ea0081p430 | Pituitary and Neuroendocrinology | ECE2022

Psychological impact of Covid-19 national lockdown on patients with Cushing’s syndrome in Italy: a case-control study

Di Paola Nicola , Barbot Mattia , Ferrante Emanuele , Ferrau Francesco , Gatto Federico , Maria Paragliola Rosa , Reimondo Giuseppe , Arnaldi Giorgio , Guarnotta Valentina , Ferrigno Rosario , Simeoli Chiara , Mantovani Giovanna , Scaroni Carla , Iasevoli Felice , Colao Annamaria , Pivonello Rosario

During the spring of 2020, a national lockdown was adopted in Italy to prevent COVID-19 pandemic spread. Restrictive measures have been associated with impaired psychological outcome in the general population. As patients with Cushing’s Syndrome (CS), including Cushing’s disease (CD), adrenal CS (ACS), and ectopic CS (ECS), are reportedly associated with a higher prevalence of anxiety, stress susceptibility, depression, and maniac episodes, during both active disease...

ea0063oc7.3 | Endocrine Connections 1 | ECE2019

Higher dose of burosumab is needed for treatment of children with sever forms of X-linked hypophosphatemia

Zhukouskaya Volha V , Audrain Christelle , Lambert Anne-Sophie , Colao Annamaria , Kamenicky Peter , Adamsbaum Catherine , Nevoux Jerome , Chaussain Catherine , Wicart Philippe , Briot Karine , Rocco Federico Di , Trabado Severine , Prie Dominique , Rothenbuhler Anya , Linglart Agnes

Background/aim: Burosumab is a monoclonal antibody against anti-FGF23, which has been recently approved for the treatment of X-linked hypophosphatemia (XLH). Beyond clinical trials, little is known about its efficacy/safety in clinical practice which is the aim of the present study.Patients/methods: Thirty-nine children with XLH were switched from conventional therapy to burosumab (starting dose 0.4 mg/kg), on the basis of following indications: non-resp...

ea0049oc9.5 | Thyroid Disease 2 | ECE2017

Selenium supplementation in the management of thyroid autoimmunity during pregnancy: results of the ‘Serena Study’ a randomized, double-blind, placebo-controlled trial

Dato Carla Di , Mantovani Giovanna , Moretti Costanzo , Greco Ermanno , Bonomi Marco , Faggiano Antongiulio , Di Sante Stefania , Giannetta Vincenzo , Petrone Luisa , Fumarola Angela , Colao Annamaria , Lenzi Andrea , Isidori Andrea M. , Giannetta Elisa

Autoimmune thyroiditis and related complications represent a growing concern during pregnancy. Selenium is frequently present in nutraceuticals recommended for thyroiditis and pregnancy, given its advocated role in immunity, fertility and thyroid function. However, most evidences come from non-controlled studies. Materials and MethodsWe designed a multicenter, randomized, double-blind, placebo-controlled trial (Serena Study: NCT01465867) to evaluate the ...

ea0041gp230 | Thyroid Cancer (1) | ECE2016

Analysis of germline VEGF-A SNPs allows the identification of a subgroup of ATA low-intermediate risk DTC (differentiated thyroid cancer) patients with poor probability to develop recurrences

Marotta Vincenzo , Sciammarella Concetta , Capasso Mario , Testori Alessandro , Gambardella Claudio , Grasso Marica , Rubino Manila , De Palma Maurizio , Grazia Chiofalo Maria , Pivonello Claudia , Pivonello Rosario , Santini Luigi , Pezzullo Luciano , Colao Annamaria , Faggiano Antongiulio

Introduction: Constitution of new blood vessels is crucial for cancer self-maintenance and progression. Neo-angiogenesis may be affected from hereditary traits, namely the presence of SNPs (single nucleotide polymorphisms) of genes involved in its regulation. VEGF-A represents the main regulator of angiogenesis. Germline SNPs of the VEGF-A gene have been associated to outcome of several cancers, but no data exist about differentiated thyroid cancer (DTC).<p class="abstext"...

ea0041ep589 | Endocrine tumours and neoplasia | ECE2016

Proposal of a two-step dynamic prognostic stratification for stage IV sporadic pancreatic neuroendocrine tumors

Marotta Vincenzo , Walter Thomas , Do Cao Christine , Tafuto Salvatore , Montesarchio Vincenzo , Arfi-Rouche Julia , Valette Pierre Jean , Lombard-Bohas Catherine , Leteurtre Emmanuelle , Borget Isabelle , Scoazec Jean Yves , Ducreux Michel , Faggiano Antongiulio , Colao Annamaria , Baudin Eric

Purpose: To validate a prognostic stratification system of overall survival (OS) in stage IV pancreatic neuroendocrine tumors (pNETs) naïve of therapy by analyzing 1) prognostic parameters at the time of stage IV diagnosis; 2) the role of spontaneous tumor slope.Patients and Methods: Multicenter retrospective study including consecutive patients diagnosed with stage IV pNET from January 1997 to March 2014. Inclusion criteria were: 1. pNET w...

ea0041ep736 | Neuroendocrinology | ECE2016

The medical treatment with pasireotide in Cushing’s disease: an Italian multicenter experience based on “Real Word Evidence”

Pivonello Rosario , Arnaldi Giorgio , Scaroni Carla Maria , Giordano Carla , Cannavo Salvatore , Iacuaniello Davide , Trementino Laura , Zilio Marialuisa , Guarnotta Valentina , Albani Adriana , Cozzolino Alessia , Michetti Grazia , Boscaro Marco , Colao Annamaria

A recent phase III clinical trial has demonstrated that the treatment with the somatostatin analogue pasireotide normalizes cortisol secretion in 15–28% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the effectiveness of 6-months pasireotide treatment on clinical and hormonal profiles in a group of CD patients with mild to moderate disease according with the real-word evidence. Thirty-two patients with CD unsuccessfully treated ...

ea0035p62 | Adrenal Medulla | ECE2014

Expression of IGF/mTOR pathway components in human pheochromocytomas and in vitro inhibition of PC12 rat pheochromocytoma cell growth by mTOR inhibitors alone and in combination with the dual IGFI-R/INS-R antagonist OSI-906

Martino Maria Cristina De , Feelders Richard A. , Dogan Fadime , Koetsveld Peter M. van , Krijger Ronald R. De , Janssen Joseph A M J L , Sprij-Mooij Diana , Lamberts Steven W. J. , Herder Wouter W de , Colao Annamaria , Pivonello Rosario , Hofland Leo J

The mTOR and IGF pathways have been suggested to play a role in the pathogenesis of pheochromocytomas (PCC). mTOR inhibitors, as sirolimus (S) and everolimus (E), as well as IGF1R antagonists could be a potential novel treatment for malignant PPC.The aim of this study was to evaluate the expression of the main components of the IGF/mTOR pathway in human PCC and to investigate the effects of the mTOR inhibitors S and E and of the IGF1R/insulin receptor (I...

ea0035p128 | Calcium and Vitamin D metabolism | ECE2014

Cinacalcet hydrochloride more efficiently controls serum calcium levels in mild-asymptomatic primary hyperparathyroidism without surgery criteria, as compared with surgical cases

Marotta Vincenzo , di Somma Carolina , Rubino Manila , del Prete Michela , Marciello Francesca , Ramundo Valeria , Sciammarella Concetta , Buonomano Pasqualina , Carratu Annachiara , de Luca di Roseto Chiara , Colao Annamaria , Faggiano Antongiulio

Context: Primary hyperparathyroidism (PHPT) is a common endocrine disease, characterized by the chronic elevation of serum calcium (Ca) levels induced by a long-standing increase of PTH concentrations. PHPT includes mild-asymptomatic and symptomatic forms. Cinacalcet is effective in lowering serum Ca levels in PHPT, but is indicated solely in mild-asymptomatic PHPT meeting surgery criteria. Management of non-surgical mild-asymptomatic PHPT is still a debated issue.<p class...

ea0035p907 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Pasireotide LAR demonstrates superior efficacy versus octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: results from a phase III, multicentre, randomized study (PAOLA)

Gadelha Monica , Bronstein Marcello , Brue Thierry , Coculescu Mihail , Fleseriu Maria , Guitelman Mirtha , Pronin Vyacheslav , Raverot Gerald , Shimon Ilan , Lievre Kayo Kodama , Fleck Juergen , Aout Mounir , Pedroncelli Alberto , Colao Annamaria

Background: Some patients with acromegaly do not achieve biochemical control despite receiving maximum-approved doses of currently available somatostatin analogues. This 24-week, randomized study assessed the multireceptor-targeted somatostatin analogue pasireotide LAR vs octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly.Methods: Eligible patients: ≥18 years with mean GH levels ≥2.5 μg/l and IGF1 level...

ea0070aep5 | Adrenal and Cardiovascular Endocrinology | ECE2020

Cytochrome P450 (CYP) 2W1 affect steroid secretion in adrenocortical cell line and tumor tissues

Altieri Barbara , Sbiera Silviu , Weigand Isabel , Volante Marco , Steinhauer Sonja , Lorey Antonia , Kendl Sabine , Kurlbaum Max , Herterich Sabine , Della Casa Silvia , Colao Annamaria , Terzolo Massimo , Kroiss Matthias , Fassnacht Martin , Ronchi Cristina

Background: The human cytochrome P450 (CYP) 2W1 is involved in the metabolism of several endogenous substrates, including lysophospholipids and fatty acids. Using a polyclonal antibody, we previously demonstrated a high CYP2W1 immunoreactivity in adrenocortical tumors, particularly in those secreting steroids. The aim of the study was to better elucidate the relationship between CYP2W1 and steroid secretion in adrenocortical carcinoma (ACC) H295R cell line and in a larger seri...